Filing Analysis
SkinHealth Systems Inc. reported the results of its annual meeting of stockholders held on June 10, 2026. Stockholders elected nine directors, ratified the appointment of Deloitte & Touche LLP as the independent auditor, and approved executive compensation on an advisory basis.
📋 Key Facts
- Annual meeting held on June 10, 2026, with a quorum of 72.08% (93,406,914 shares represented).
- Nine directors were elected for one-year terms expiring at the 2027 annual meeting.
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Executive compensation was approved on an advisory, non-binding basis with 58,604,735 votes in favor.
SkinHealth Systems Inc. filed an amendment to a previous 8-K to provide the executed Separation Agreement for Ronald Menezes, the former Chief Revenue Officer, who was terminated without cause on May 5, 2026.
📋 Key Facts
- Ronald Menezes was terminated as Chief Revenue Officer effective May 6, 2026.
- Termination was 'without cause' and not due to disagreements over financial reporting or operations.
- A Separation Agreement was executed on May 15, 2026.
- Severance package includes $463,000 in cash payable over 12 months.
- Mr. Menezes is eligible for a pro-rata 2026 annual bonus payable in March 2027.
- The company will reimburse the employer portion of COBRA premiums during the severance period.
SkinHealth Systems Inc. received a deficiency notice from Nasdaq on May 8, 2026, because its Class A Common Stock failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. The company has 180 calendar days, or until November 4, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of ten consecutive business days.
🚩 Red Flags
- Failure to maintain the minimum $1.00 bid price requirement for 30 consecutive business days.
- Explicit mention of a potential reverse stock split as a necessary action to cure the deficiency.
📋 Key Facts
- Notice received from Nasdaq on May 8, 2026, regarding non-compliance with Listing Rule 5550(a)(2).
- Closing bid price was below $1.00 from March 26, 2026, through May 7, 2026.
- The company has until November 4, 2026, to regain compliance.
- A second 180-day extension may be available if the company meets other listing standards and intends to cure the deficiency, potentially via a reverse stock split.
- The stock continues to trade on The Nasdaq Capital Market under the symbol 'SKIN' during the compliance period.
SkinHealth Systems Inc. reported its financial results for the fiscal quarter ended March 31, 2026. The filing includes a press release and notice of a conference call to discuss the results, including non-GAAP financial reconciliations.
📋 Key Facts
- The report covers the fiscal quarter ended March 31, 2026.
- The filing was made on May 7, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- The company provided non-GAAP financial information and a corresponding reconciliation to GAAP results in Exhibit 99.1.
- The company identified its website and SEC filings as primary channels for disclosing material non-public information under Regulation FD.
SkinHealth Systems Inc. terminated Chief Revenue Officer Ronald Menezes without cause on May 5, 2026. The company is currently negotiating a separation agreement and will file an amendment once terms are finalized.
🚩 Red Flags
- Sudden departure of the executive responsible for revenue generation (CRO).
- The lack of an immediate successor or interim appointment mentioned in the filing.
📋 Key Facts
- Ronald Menezes was terminated as Chief Revenue Officer effective May 5, 2026.
- The termination was classified as 'without cause'.
- The company stated there were no disagreements regarding financial reporting, operations, policies, or practices.
- A separation agreement is currently being negotiated and terms have not yet been determined.
- An amendment to the 8-K will be filed within four business days of finalizing the separation agreement.
SkinHealth Systems Inc. (formerly The Beauty Health Company) announced a significant board refresh and a corporate name change. The company appointed three new independent directors, including the former CEO of Elizabeth Arden, while two existing directors will not stand for reelection at the 2026 Annual Meeting.
🚩 Red Flags
- Multiple 8-K items (5.02 and 5.03) filed in a single report.
- Simultaneous departure of two board members following the appointment of three others suggests a significant shift in governance or strategy.
📋 Key Facts
- Appointed Kenneth Tripp (SVP at Zimmer Biomet), Dr. Sachin Shridharani (Plastic Surgeon), and E. Scott Beattie (former CEO of Elizabeth Arden) to the Board effective April 17, 2026.
- The Board was temporarily expanded from 9 to 11 members to accommodate the new appointments.
- Directors Desiree Gruber and Dr. Philippe Schaison will not be nominated for reelection at the 2026 Annual Meeting, at which point the board will return to 9 members.
- Changed corporate name from 'The Beauty Health Company' to 'SkinHealth Systems Inc.' effective April 22, 2026.
- Amended bylaws to comply with SEC Rule 14a-19 (Universal Proxy Rules) and to reflect the name change.
The Beauty Health Company reported its financial results for the fourth quarter and full fiscal year ended December 31, 2025. The filing includes a press release and announces a conference call to discuss these results.
📋 Key Facts
- Event date and filing date: March 12, 2026
- Reporting period: Fiscal quarter and year ended December 31, 2025
- Item 2.02: Results of Operations and Financial Condition
- Includes non-GAAP to GAAP financial reconciliations in the attached press release (Exhibit 99.1)
- Signed by Michael Monahan, Chief Financial Officer
The Beauty Health Company has reached a settlement agreement in a consolidated stockholder derivative action pending in the Delaware Court of Chancery. The settlement, which is subject to court approval, aims to resolve all claims in the litigation captioned Elstein v. Saunders et al.
🚩 Red Flags
- The existence of a consolidated stockholder derivative action suggests underlying allegations of breach of fiduciary duty or mismanagement by company leadership.
- The litigation involves multiple parties and was significant enough to require a consolidated action in the Delaware Court of Chancery.
📋 Key Facts
- The Stipulation of Settlement was entered into on February 9, 2026.
- The litigation is titled Elstein v. Saunders et al. (In re The Beauty Health Co. Consolidated S’holder Litig.), C.A. No. 2024-0114-LWW.
- Notice of the settlement was provided to stockholders of record as of February 20, 2026.
- The settlement remains subject to final approval by the Delaware Court of Chancery.
- The claims being settled were previously described in the Company’s 10-Q filed on November 6, 2025.